HBsAg kinetics in chronic hepatitis D during interferon therapy: on-treatment prediction of response

G. A. Niro, A. Smedile, R. Fontana, A. Olivero, A. Ciancio, M. R. Valvano, F. Pittaluga, N. Coppola, H. Wedemeyer, K. Zachou, A. Marrone, M. Fasano, G. Lotti, P. Andreone, A. Iacobellis, A. Andriulli, M. Rizzetto

Research output: Contribution to journalArticlepeer-review


Background: Therapy of chronic hepatitis D with Interferon is successful when testing for HDV-RNA turns negative. This end-point is disputed. Aim: To assess the role of serum hepatitis B surface antigen (HBsAg) in the clearance of HDV-RNA in pegylated interferon (Peg-IFN)-treated chronic hepatitis D (CHD). Methods: Sixty-two patients with CHD, treated with Peg-IFN, were considered. The patients belonged to three groups: 14 patients cleared the HBsAg and HDV-RNA (responders, R), 12 cleared the HDV-RNA remaining positive for HBsAg (partial responders, PR) and 36 cleared neither the HBsAg nor the HDV-RNA (nonresponders, NR). Results: In responders, at baseline the median value (mv) of HBsAg and HDV-RNA was 1187 and 188 663 IU/mL. By month 6 of therapy, HBsAg declined to less than 1000 IU/mL and HDV-RNA was undetectable in 12 patients. In NR, the pre-therapy median value of HBsAg and HDV viremia was 6577 and 676 319 IU/mL. There was no significant reduction of antigen at month 6; after a decline, HDV-RNA rebounded to baseline levels. In PR, the median value of baseline HBsAg was 7031 IU/mL; it declined at month 6 in the majority. HDV-RNA progressively declined from an initial median value of 171 405 IU/mL. HBsAg

Original languageEnglish
Pages (from-to)620-628
Number of pages9
JournalAlimentary Pharmacology and Therapeutics
Issue number6
Publication statusPublished - Sep 1 2016

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology (medical)


Dive into the research topics of 'HBsAg kinetics in chronic hepatitis D during interferon therapy: on-treatment prediction of response'. Together they form a unique fingerprint.

Cite this